Medications like Ozempic, Wegovy, and Zepbound have helped many Americans lose weight, but there are still some misconceptions about these medications and metabolic health. Centre Spring MD founder ...

The study, conducted 4,489 of US adults (including 332 currently taking a GLP-1 and 151 no longer on the medication) found that most individuals taking GLP-1s for weight loss do not expect to stay on ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain following bariatric surgery, a Swiss real-world study reveals.

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat.

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

Nestle SA is launching GLP-1-friendly beverages under its Boost brand that contain a proprietary whey protein microgel technology, according to the company. Nestle said the innovation allows for more ...

GLP-1 agonists are a true black-swan event.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.